These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22386755)

  • 21. Urinary protein biomarker panel for the detection of recurrent bladder cancer.
    Rosser CJ; Chang M; Dai Y; Ross S; Mengual L; Alcaraz A; Goodison S
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1340-5. PubMed ID: 24714076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
    McNeil BK; Sorbellini M; Grubb RL; Apolo A; Cecchi F; Athauda G; Cohen B; Giubellino A; Simpson H; Agarwal PK; Coleman J; Getzenberg RH; Netto GJ; Shih J; Linehan WM; Pinto PA; Bottaro DP
    J Transl Med; 2014 Oct; 12():199. PubMed ID: 25335552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.
    Erdmann K; Salomo K; Klimova A; Heberling U; Lohse-Fischer A; Fuehrer R; Thomas C; Roeder I; Froehner M; Wirth MP; Fuessel S
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology.
    Eissa S; Salem AM; Zohny SF; Hegazy MG
    Cancer Biomark; 2007; 3(6):275-85. PubMed ID: 18048965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
    Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
    Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer.
    Cheng D; Liang B; Li Y
    Tumori; 2012 Nov; 98(6):762-7. PubMed ID: 23389364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors.
    Chautard D; Daver A; Bocquillon V; Verriele V; Colls P; Bertrand G; Soret JY
    Eur Urol; 2000 Dec; 38(6):686-90. PubMed ID: 11111185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder.
    Irani J; Desgrandchamps F; Millet C; Toubert ME; Bon D; Aubert J; Le Duc A
    Eur Urol; 1999 Feb; 35(2):89-92. PubMed ID: 9933800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
    Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
    Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
    Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
    Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis].
    Sun Y; He H; Ma Q; Wang XY; Yang L; He DL
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2507-12. PubMed ID: 16321281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human complement factor H related protein test for monitoring bladder cancer.
    Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
    J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
    Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
    Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
    Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
    Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the BTA tests for the detection of bilharzial related bladder cancer: the Cairo experience.
    Khaled HM; Abdel-Salam I; Abdel-Gawad M; Metwally A; El-Demerdash S; El-Didi M; Morsi A; Ishak L
    Eur Urol; 2001 Jan; 39(1):91-4. PubMed ID: 11173945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multiplex immunoassay for the non-invasive detection of bladder cancer.
    Shimizu Y; Furuya H; Bryant Greenwood P; Chan O; Dai Y; Thornquist MD; Goodison S; Rosser CJ
    J Transl Med; 2016 Jan; 14():31. PubMed ID: 26830497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.